Vicapsys Life Sciences Provides Shareholder Update on VICAPSYN(TM) Program Advancing Toward Phase 1 Human Clinical Trial, Vertically Integrated With the Company's Indian Health Service Strategy

What happened: Vicapsys Life Sciences said VICAPSYN, its immune-isolation technology for islet cell transplantation in type 1 diabetes, remains an active asset and is advancing toward a Phase 1 human clinical trial under its new operating structure. Key numbers: Vertex acquired Semma Therapeutics for $950 million Why it matters: The company is integrating the program with its Indian Health Service and federal health channel, and is exploring partnerships in Argentina for a possible Latin American licensing arm. Vertex's VX-264 device was discontinued in 2025 after missing efficacy goals. Market: +0.6% today ($562.09), +24.3% YTD, 0.6x vol — as of 16:48 UTC Verified: Q3_2026 (Nov 2) EPS $4.36 vs $4.36 est; next print ~Feb 1

Vicapsys Life Sciences said VICAPSYN, its immune-isolation technology for islet cell transplantation in type 1 diabetes, remains an active asset and is advancing toward a Phase 1 human clinical trial under its new operating structure.

The company is integrating the program with its Indian Health Service and federal health channel, and is exploring partnerships in Argentina for a possible Latin American licensing arm. Vertex's VX-264 device was discontinued in 2025 after missing efficacy goals. Market: +0.6% today ($562.09), +24.3% YTD, 0.6x vol — as of 16:48 UTC Verified: Q3_2026 (Nov 2) EPS $4.36 vs $4.36 est; next print ~Feb 1